In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection.
A novel oxazolidinone, AM 7359, was evaluated in two mouse models of Staphylococcus aureus infection. AM 7359 and linezolid were equally efficacious in a methicillin-susceptible S. aureus organ burden model and a methicillin-resistant S. aureus localized infection model. However, AM 7359 was eightfold more efficacious than linezolid against a linezolid- and methicillin-resistant S. aureus strain in this localized (thigh) infection model.
Gill
Charles J
CJ
Department of Infectious Diseases, Merck Research Laboratories, Rahway, NJ 07065, USA. charles_gill@merck.com
Abruzzo
George K
GK
Flattery
Amy M
AM
Misura
Andrew S
AS
Bartizal
Ken
K
Hickey
Emily J
EJ
D000081:Acetamides / Q000627:therapeutic use; D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004305:Dose-Response Relationship, Drug; D007275:Injections, Intravenous; D000069349:Linezolid; D016106:Methicillin Resistance; D051379:Mice; D008809:Mice, Inbred C3H; D023303:Oxazolidinones / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology
C523767:AM-7359; D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000069349:Linezolid